Sentences with phrase «cancer immunology program»

Dr. Lieping Chen currently serves as the United Technologies Corporation Professor in Cancer Research, Professor of Immunobiology, Dermatology and Medical Oncology at Yale School of Medicine and co-Director of the Cancer Immunology Program of Yale Cancer Center in New Haven, CT..

She is a member of the Department of Pathology at Brigham and Women's Hospital, an Associate Member at the Broad Institute of MIT and Harvard, and Leader of the Cancer Immunology Program at the Dana - Farber / Harvard Cancer Center.

«Our research shows that the protein GSK3 plays a crucial role in helping B cells meet the energy needs of their distinct states,» says Robert Rickert, Ph.D., director of the Tumor Microenvironment and Cancer Immunology Program at Sanford Burnham Prebys Medical Discovery Institute (SBP).

«This pathway is very important in balancing immunity against pathogens and tolerance against self,» says Zihai Li, M.D., Ph.D., professor and chair of Microbiology and Immunology at MUSC, co-leader of the Cancer Immunology Program at the MUSC Hollings Cancer Center, and senior author for this study.

Tumors are home to diverse immune cell types, some of which remain much less explored than T cells and could also control cancer progression» says Mikael Pittet, PhD, director of the Cancer Immunology Program in the MGH Center for Systems Biology and senior author of the Science paper.

«Pancreatic cancer cells are deadly because they program nearby immune cells to permit the tumors to survive and grow,» says study author George Miller, MD, head of the Cancer Immunology Program at Perlmutter and vice chair for research in the Department of Surgery at NYU Langone.

«These exciting results indicate that there is a new standard of care option for a population of head and neck cancer patients with no other treatment options,» said the trial's international co-chair Robert Ferris, M.D., Ph.D., UPMC Endowed Professor, and chief of the Division of Head and Neck Surgery and co-leader of the Cancer Immunology Program at UPCI.

Not exact matches

«Dendritic cells are essential for prompting the immune response against malignant cells and for driving the clinical success of cancer immunotherapy, but their function is often defective in cancer patients,» said Dmitry I. Gabrilovich, M.D., Ph.D., Christopher M. Davis Professor and program leader of the Immunology, Microenvironment & Metastasis Program at program leader of the Immunology, Microenvironment & Metastasis Program at Program at Wistar.

«What he showed us is turning the immune system on isn't enough; the crucial step is to make sure it doesn't turn itself off,» says Antoni Ribas, director of the tumor immunology program at UCLA's Jonsson Comprehensive Cancer Center.

In his day job, at the University of Texas MD Anderson Cancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortCancer Center in Houston, Allison serves as chair of the immunology department, deputy director of the David H. Koch Center for Applied Research of Genitourinary Cancers and executive director of the immunotherapy division of the Moon Shots Program, a multidisciplinary effort tackling cancer mortcancer mortality.

«We had a hypothesis about how these treatments would work together, and when we did biopsies of patients» tumors we found that they were cooperating in just the way we thought they would,» says lead author Antoni Ribas, director of the Immunology Program at the UCLA Jonsson Comprehensive Cancer Center.

This new approach «represents an important advancement,» said Felicia Goodrum Sterling, the director of the graduate program in immunology at the University of Arizona Cancer Center, who was not involved in the research.

PHILADELPHIA --(July 11, 2017)-- Researchers at The Wistar Institute, an international leader in biomedical research in the fields of cancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (Mcancer, immunology and infectious diseases, with collaborators at Indiana University Melvin and Bren Simon Cancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MCancer Center and Syndax Pharmaceuticals, Inc., (Nasdaq: SNDX) announce the results of a preclinical study demonstrating that entinostat, Syndax's oral, Class - I histone deacetylase inhibitor, enhances the antitumor effect of PD - 1 (programmed death receptor - 1) blockade through the inhibition of myeloid derived suppressor cells (MDSCs).

«We have experiments in mice that show that the combined use of PD - 1 antibody and poly - IC is synergistic for the recognition of tumors and an antitumor response mediated by T - cells,» says Dr. Esteban Celis, co-leader of the Cancer Immunology, Inflammation and Tolerance program at the Georgia Cancer Center at Augusta University.

Dr. Kunle Odunsi is the deputy director of the Roswell Park Cancer Institute, where he also serves as the chair of the Department of Gynecologic Oncology, the executive director of the Center for Immunotherapy, and the co-Leader of the Tumor Immunology and Immunotherapy research program.

In addition to Amgen's work to improve cancer patient treatment through science - based innovation, CRI will also recognize the company's commitment to the broader scientific and patient communities, both through its support of CRI's Cancer Immunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapy rescancer patient treatment through science - based innovation, CRI will also recognize the company's commitment to the broader scientific and patient communities, both through its support of CRI's Cancer Immunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapy resCancer Immunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapy resCancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapy rescancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapy rescancer immunology and immunotherapy research.

Cancer Research Institute inaugurates its Investigator Award Program for junior faculty members working in immunology and tumor immunology.

CRI establishes its Postdoctoral Fellowship Program, the Institute's oldest formal grant program and the first program of its kind in the world, «for the support of qualified individuals who wish to receive training and experience in experimental or clinical cancer immunology.Program, the Institute's oldest formal grant program and the first program of its kind in the world, «for the support of qualified individuals who wish to receive training and experience in experimental or clinical cancer immunology.program and the first program of its kind in the world, «for the support of qualified individuals who wish to receive training and experience in experimental or clinical cancer immunology.program of its kind in the world, «for the support of qualified individuals who wish to receive training and experience in experimental or clinical cancer immunology.»

Dr. Levitsky: This is the first time that Roche has formally established a cancer immunology and immunotherapy research and development program within its structure.

The Center for Cancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurCancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its rImmunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its rimmunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its rimmunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurcancer and prevent its recurrence.

Since 2000 Head of Lymphocyte Activation Unit Division of Immunology, Transplantation and Infectious Diseases Program in Immunology, Bio-Immuno-gene therapy of Cancer, IRCCS Ospedale San Raffaele, Milan, Italy 1998 - 1999 Research Associate Department of Molecular Biology and Functional Genomic, IRCCS Ospedale San Raffaele, Milan, Italy 1993 - 1998 Postdoctoral Associate Department of Microbiology University of Minnesota, Medical School Minneapolis, MN, USA 1991 - 1992 Department of Pharmacology, New York University, New York, USA 1989 - 1991 Department of Biomedical Science and Oncology, Turin, Italy 1988 - 1989 Research Fellow Department of Biomedical Science and Oncology, Turin, Italy 1989 - 1992 Ph.D. student in Molecular Oncology 1986 - 1988 Undergraduate student Department of Biomedical Science and Oncology, Turin, Italy

Research in the Immunology, Microenvironment and Metastasis program is aimed at 1) merging basic mechanistic understanding of multidisciplinary pathways of host - tumor interactions and metastatic dissemination with novel translational opportunities for diseases diagnosis and immunotherapy, as well as 2) investigating mechanisms regulating immune responses in cancer and their potential therapeutic manipulation.

Other funding was from the Cancer Research Institute, the Academy of Finland Centre of Excellence in Molecular Systems, Immunology and Physiology Research program, the Damon Runyon Cancer Research Foundation (DRG -2069-11), and the National Science Foundation.

Christophe Quéva, chief scientific officer, commented «The building of a custom designed R&D facility demonstrates our commitment to our cancer immunology research programs and will enable us to recruit additional qualified scientists needed in both our drug discovery and development.»

Much of Rudensky's career unfolded at Sloan - Kettering Institute of the Memorial Sloan - Kettering Cancer Center in New York City, where he arrived in 2008 and is currently chair of the immunology program and director of the Ludwig Center for Cancer Immunotherapy.

From Yale, Sasha went on to take a position at the University of Washington in Seattle, where he would stay for 16 years, before moving to New York first as a member of the Immunology Program at the Sloan Kettering Institute and subsequently assuming his current role as the chair of the Immunology Program at the Sloan Kettering Institute and director of the Ludwig Center at the Memorial Sloan Kettering Cancer Center in New York.

From 1996 - 2003 he served as an Assistant Professor of Medicine in the Section of Oncology and as co-Director of the Immunology Research Program of the Yale Cancer Center.

«His arrival at Chicago will bring new strengths to the department of pathology and should also support our established programs in transplant immunology and cancer biology.

He has been previously co-director of the Program of Immunology and Bio-Immuno therapy of Cancer and coordinator of the Cancer Immunotherapy and Gene Therapy Program.

Dr. Antoni Ribas is the director of the Tumor Immunology Program at the University of California, Los Angeles Comprehensive Cancer Center, and the chair of the Melanoma Committee at SWOG.

CRI Scientific Advisory Council director Lloyd J. Old, M.D., a pioneer responsible for many seminal discoveries in the field, is a senior expert in tumor immunology who for the past four decades has guided the scientific vision for CRI and who currently leads the Institute's global cancer vaccine research programs.

The CRI Irvington Postdoctoral Fellowship Program supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology.

Vice President, Scientific Operations Herbert Kean, M.D., Family Endowed Chair Professor Director, HIV - 1 Immunopathogenesis Laboratory Professor, Translational Tumor Immunology Program Professor, Vaccine & Immunotherapy Center Associate Director for Shared Facilities, Wistar Cancer Center

Executive Vice President Director, Vaccine & Immunotherapy Center W.W. Smith Charitable Trust Professor in Cancer Research Professor, Immunology, Microenvironment & Metastasis Program

In 2016, Dmitry I. Gabrilovich, M.D., Ph.D., program leader of Wistar's Translational Tumor Immunology program, and his research team identified a marker for myeloid - derived suppressor cells (MDSCs), a population of immune cells implicated in tumor resistance to various types of cancer treatment, including targeted therapies, chemotherapy and immunotherapy.

Dario C. Altieri, M.D. President and Chief Executive Officer Director, The Wistar Institute Cancer Center Robert and Penny Fox Distinguished Professor Professor, Immunology, Microenvironment & Metastasis Program

The program will focus on «Translating Science into Survival» and feature talks from more than 60 leaders in the field covering all areas of inquiry in cancer immunology and immunotherapy.